Last reviewed · How we verify
Post - Vaccination (vaccination)
Pfizer's vaccination drug is a vaccine that helps the immune system develop immunity from diseases. It contains a weakened or killed virus or microorganism. The key indications include viral-related symptoms, injection site pain, fever, inflammation, and fatigue. This drug is marketed and has a large number of trials and publications. It is a first-in-class vaccine that provides herd immunity and protects immunocompromised individuals. The commercial significance of this drug is its ability to prevent infectious diseases. Pfizer's vaccination drug is a significant development in the pharma industry.
At a glance
| Generic name | vaccination |
|---|---|
| Sponsor | Pfizer |
| Drug class | Inactivated Poliovirus Vaccine [EPC] |
| Target | Immune system |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- viral-related symptoms
- injection site pain
- fever
- inflammation
- fatigue
- skin discomfort
Common side effects
Drug interactions
- Live Attenuated Vaccines
- Immunosuppressants
- Interferons
- Corticosteroids
- Antibiotics
- Antivirals
- Antifungals
- Antihistamines
- Anticholinergics
- Sedatives
- Anesthetics
- Cancer Chemotherapy
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) (NA)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines (PHASE1, PHASE2)
- Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (PHASE2)
- Opioid, HIV and Immune System (PHASE4)
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products (PHASE4)
- Blood Donor CVD 5000 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Post - Vaccination CI brief — competitive landscape report
- Post - Vaccination updates RSS · CI watch RSS
- Pfizer portfolio CI